BIRC5 and neoplasm: Beside model antigens like the HPV E6/E7 in TC‐1 and the β‐galactosidase in CT26, additional models would also allow us to test therapeutic efficacy of DCVacc/VSV‐GP for “real” tumor antigens like the gp100/Trp2 antigens in B16, the survivin in LLC or the Adpgk1 in MC38.